Does Anthem (Elevance Health) Cover AndroGel?

Anthem's Coverage Policy for AndroGel

Anthem (Elevance Health) classifies AndroGel as a covered brand-name medication for the treatment of male hypogonadism on its commercial PPO and HMO formularies, subject to utilization management controls. Coverage is not automatic. Your prescriber must submit a prior authorization request and, in most cases, you must have tried and failed a lower-cost testosterone formulation first.

Anthem's clinical policy bulletins for testosterone replacement therapy (TRT) follow the Endocrine Society's 2018 clinical practice guideline, which recommends TRT only for men with unequivocally low serum testosterone confirmed on at least two morning samples, combined with signs and symptoms of hypogonadism. Anthem applies this standard directly to its PA criteria. Plans administered under Anthem subsidiaries (Empire BlueCross BlueShield, Wellpoint, Anthem Blue Cross) use the same national policy, though regional formulary placement can vary by state filing.

Anthem does not cover AndroGel for off-label purposes such as age-related testosterone decline without documented clinical hypogonadism, athletic performance enhancement, or weight loss. The FDA-approved labeling for AndroGel restricts the indication to males with conditions associated with a deficiency or absence of endogenous testosterone.

Formulary Tier and Cost Breakdown

AndroGel typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of Anthem's commercial drug formulary, depending on your specific plan document and state. The distinction matters. A lot.

On a Tier 3 placement, expect a copay between $50 and $75 per 30-day supply after meeting your pharmacy deductible. On Tier 4, copays climb to $100 to $150, or shift to coinsurance of 25% to 40% of the drug's negotiated rate. For a medication with a list price near $510 per month, a 30% coinsurance translates to roughly $150 out of pocket per fill.

Generic testosterone gel 1% (authorized generic versions of AndroGel) is available on most Anthem formularies at Tier 2 (preferred generic), with copays commonly in the $20 to $40 range. This price difference is precisely why Anthem imposes step therapy: the generic contains the same active ingredient, same concentration, and same delivery mechanism. The T-Trials, a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with low testosterone, demonstrated that testosterone gel (the same 1% formulation used in AndroGel) improved sexual function, physical activity, and mood over 12 months. These findings apply equally to brand and generic formulations.

To check your specific plan's tier placement, log into the Anthem member portal at anthem.com, manage to "Find a Drug," and search for testosterone gel. The result will show your plan's tier, any quantity limits, and whether step therapy applies.

Prior Authorization Requirements

Anthem's prior authorization for AndroGel requires your prescriber to document several clinical criteria. The PA form asks for confirmation that the patient is an adult male with a clinical diagnosis of hypogonadism supported by two serum total testosterone levels drawn before 10:00 AM on separate days, each falling below approximately 300 ng/dL (the threshold varies slightly by lab assay and Anthem policy version).

Your prescriber must also confirm that secondary causes of low testosterone have been evaluated. The Endocrine Society guideline specifies that clinicians should measure serum LH and FSH to distinguish primary from secondary hypogonadism, and should screen for conditions like hyperprolactinemia, iron overload, and obstructive sleep apnea before initiating TRT. Anthem's PA form mirrors this expectation.

Required documentation typically includes:

• Two pre-treatment morning serum total testosterone results below 300 ng/dL
• Clinical signs and symptoms (fatigue, decreased libido, erectile dysfunction, reduced lean mass, depressed mood)
• LH and FSH levels to classify hypogonadism type
• PSA and hematocrit at baseline (Anthem may require these to confirm no contraindications)
• Documentation that the patient has no contraindications listed in the FDA label (breast or prostate cancer, polycythemia, untreated severe sleep apnea)

PA approval is usually granted for 12 months. Anthem's pharmacy benefit manager processes most PA requests within 24 to 72 hours. Urgent or expedited requests can be completed within 24 hours when the prescriber indicates clinical urgency.

A 2020 analysis published in JAMA Internal Medicine found that prior authorization denials for prescription medications led to treatment abandonment in approximately 30% to 40% of cases across commercial insurers. For testosterone gel specifically, the most common denial reason is failure to provide two qualifying morning testosterone levels.

Step Therapy: What You Must Try First

Anthem requires step therapy for AndroGel on nearly all commercial plans. This means your prescriber must demonstrate that you tried a preferred alternative and that it was ineffective, caused intolerable side effects, or was contraindicated before Anthem will authorize the brand product.

The preferred first-step agents on most Anthem formularies include generic testosterone gel 1%, generic testosterone cypionate injection (intramuscular, typically dosed every 1 to 2 weeks), and in some plan designs, testosterone enanthate injection. These are substantially less expensive. Generic testosterone cypionate 200 mg/mL, for example, costs roughly $30 to $60 per month at most pharmacies, while generic testosterone gel 1% runs $80 to $150 per month without additional discount cards.

To satisfy step therapy, your prescriber typically must document a 60- to 90-day trial of the preferred agent. Acceptable reasons for step therapy override include:

• Documented allergic reaction or hypersensitivity to an ingredient in the generic formulation
• Therapeutic failure (testosterone levels remained below target or symptoms persisted despite adequate dosing and adherence)
• Intolerable adverse effects (severe skin irritation at application site, for instance)
• A clinical reason why the first-step agent is contraindicated (needle phobia alone does not universally qualify as a contraindication, but some Anthem plan documents do accept it as a reason to bypass injectable step therapy)

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and past president of the Endocrine Society, has noted: "The bioavailability and clinical outcomes of brand-name and authorized-generic testosterone gels are essentially identical. The choice between them is a matter of patient preference and insurance coverage, not pharmacology." This statement reflects the clinical consensus that step therapy through a generic gel before approving brand AndroGel is medically reasonable, even if inconvenient.

How to Appeal a Denied AndroGel Claim

If Anthem denies your prior authorization for AndroGel, you have the right to appeal. The denial letter (called an Adverse Benefit Determination) will specify the reason for denial and outline your appeal options. Anthem provides two levels of internal appeal before you can request an external review.

Level 1: Internal Appeal. You or your prescriber must submit a written appeal within 180 days of the denial. Include a letter of medical necessity from your prescriber explaining why AndroGel specifically (rather than a generic alternative) is required. Attach supporting lab work, clinical notes, and documentation of any failed step-therapy trials. Anthem must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent clinical situations.

Level 2: Second Internal Appeal. If the first appeal is denied, most Anthem plans offer a second-level review by a physician reviewer who was not involved in the initial decision. Submit additional supporting evidence if available, such as peer-reviewed literature supporting the use of brand-name testosterone gel in your clinical scenario.

External Review (Independent Review Organization). After exhausting internal appeals, federal and state law entitles you to an independent external review. Anthem must inform you of this right in its final denial letter. The external IRO is a third-party organization that reviews the medical evidence independently. The IRO decision is binding on Anthem. Most states process external reviews within 45 days, or within 72 hours for expedited cases. The ACA Section 2719 establishes these external review protections for all non-grandfathered health plans.

A practical tip: peer-to-peer review requests (where your prescriber speaks directly with Anthem's medical director) often resolve denials faster than written appeals. Ask your prescriber's office to request a peer-to-peer call within the first 5 business days of receiving a denial.

Using the AbbVie Savings Card with Anthem

AbbVie, the manufacturer of AndroGel, offers a copay savings card that can reduce your out-of-pocket cost to as low as $0 per month, up to a maximum annual benefit (typically $3,600 per year, though terms change periodically). This card works alongside commercial insurance, including Anthem plans.

There are limits. The savings card cannot be used with government-funded insurance: Medicare Part D, Medicaid, TRICARE, and VA benefits are excluded. If your Anthem plan is an employer-sponsored commercial plan or an individual marketplace plan (non-subsidized), you are generally eligible.

To activate the card, visit the manufacturer's patient support website or ask your prescriber's office for an enrollment form. The card functions as a secondary payer at the pharmacy: Anthem processes the claim first, and the savings card covers part or all of your remaining copay or coinsurance.

One caution: copay assistance payments typically do not count toward your plan's annual deductible or out-of-pocket maximum under Anthem's copay accumulator programs. Anthem has implemented copay accumulator adjustments on many plans since 2020, meaning the manufacturer's payment reduces your pharmacy bill but does not reduce the amount you still owe toward your deductible. Check your plan's Summary of Benefits and Coverage or call Anthem member services to confirm whether your plan uses a copay accumulator.

Anthem Medicare Advantage and AndroGel

Anthem's Medicare Advantage plans (branded as Anthem Blue Cross Medicare Advantage or similar regional names) handle testosterone gel coverage through Medicare Part D pharmacy benefits. Part D formulary placement for AndroGel varies by plan, but it is frequently placed on Tier 4 or Tier 5 (specialty tier) with coinsurance of 25% to 33%.

Medicare Part D plans follow CMS coverage determination guidelines. Testosterone replacement is a covered Part D benefit for male hypogonadism, but the same prior authorization and quantity limit rules apply. The Endocrine Society's clinical practice guideline recommends monitoring hematocrit at baseline, 3 to 6 months after starting therapy, and annually thereafter. Anthem Medicare Advantage plans may require documentation of this monitoring for PA renewal.

The Extra Help (Low Income Subsidy) program can substantially reduce Part D copays for qualifying patients. Monthly income limits for 2026 Extra Help eligibility should be confirmed at ssa.gov or by calling 1-800-MEDICARE.

Alternatives If Anthem Won't Cover AndroGel

If you cannot obtain Anthem approval for brand AndroGel after exhausting appeals, several options remain.

Generic testosterone gel 1%. Bioequivalent to AndroGel, available at Tier 2 copays on most Anthem plans. This is the simplest alternative and is clinically equivalent.

Testosterone cypionate injection. Administered intramuscularly every 1 to 2 weeks, or subcutaneously weekly in some protocols. Cost: approximately $30 to $60 per month. The Endocrine Society guideline lists injectable testosterone esters as first-line TRT options with well-established efficacy data.

Testosterone nasal gel (Natesto). A short-acting testosterone delivered via nasal application three times daily. It may be on a different formulary tier than transdermal gels and could bypass Anthem's transdermal step therapy requirements.

Compounded testosterone cream. Available from compounding pharmacies, often at $40 to $100 per month. Compounded preparations are not FDA-approved and are not covered by Anthem, but the out-of-pocket cost may be lower than brand AndroGel copays.

AbbVie Patient Assistance Program. For uninsured or underinsured patients, AbbVie offers a patient assistance program that may provide AndroGel at no cost. Eligibility is income-based, typically capped at 400% of the federal poverty level.

Monitoring Requirements Under Anthem's Policy

Anthem's PA renewal process (typically annual) requires updated clinical documentation confirming that TRT remains medically necessary and that safety monitoring is current. The Endocrine Society recommends measuring serum testosterone levels 2 to 4 weeks after initiation or dose adjustment (for gels, measured 2 to 8 hours after application), then every 6 to 12 months.

Required monitoring labs for PA renewal generally include serum total testosterone (target range 400 to 700 ng/dL on therapy), hematocrit (discontinue or reduce dose if hematocrit exceeds 54%), PSA (in men over 40, with urology referral for PSA above 4.0 ng/mL or a rise exceeding 1.4 ng/mL over 12 months), and lipid panel. A bone mineral density scan may be warranted after 1 to 2 years of therapy in men with baseline osteoporosis, as the T-Trials bone substudy demonstrated that testosterone gel significantly increased volumetric bone mineral density and estimated bone strength in the spine and hip over 12 months.

Keep copies of all lab results. If your prescriber's office submits the PA renewal without attaching current labs, Anthem will deny the renewal, creating an avoidable gap in therapy. Set a calendar reminder 30 days before your PA expiration date to schedule labs and initiate the renewal.